2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          The activity of ceftolozane-tazobactam was compared to the activities of 7 antimicrobials against 3,851 Pseudomonas aeruginosa isolates collected from 32 U.S. hospitals in the Program to Assess Ceftolozane-Tazobactam Susceptibility from 2012 to 2015. Ceftolozane-tazobactam and comparator susceptibilities were determined using the CLSI broth microdilution method at a central monitoring laboratory. For ceftolozane-tazobactam, 97.0% of the isolates were susceptible. Susceptibilities of the other antibacterials tested were: amikacin, 96.9%; cefepime, 85.9%; ceftazidime, 85.1%; colistin, 99.2%; levofloxacin, 76.6%; meropenem, 81.8%; and piperacillin-tazobactam, 80.4%. Of the 699 (18.1%) meropenem-nonsusceptible P. aeruginosa isolates, 87.6% were susceptible to ceftolozane-tazobactam. Six hundred seven isolates (15.8%) were classified as multidrug resistant (MDR), and 363 (9.4%) were classified as extensively drug resistant (XDR). Only 1 isolate was considered pandrug resistant, which was resistant to all tested agents, including colistin. Of the 607 MDR isolates, 84.9% were ceftolozane-tazobactam susceptible, and 76.9% of XDR isolates were ceftolozane-tazobactam susceptible. In vitro activity against drug-resistant P. aeruginosa indicates ceftolozane-tazobactam may be an important agent in treating serious bacterial infections.

          Related collections

          Author and article information

          Journal
          Antimicrob Agents Chemother
          Antimicrob. Agents Chemother
          aac
          aac
          AAC
          Antimicrobial Agents and Chemotherapy
          American Society for Microbiology (1752 N St., N.W., Washington, DC )
          0066-4804
          1098-6596
          8 May 2017
          27 June 2017
          July 2017
          : 61
          : 7
          : e00465-17
          Affiliations
          [a ]JMI Laboratories, North Liberty, Iowa, USA
          [b ]University of Iowa, Iowa City, Iowa, USA
          Author notes
          Address correspondence to Dee Shortridge, dee-shortridge@ 123456jmilabs.com .

          Citation Shortridge D, Castanheira M, Pfaller MA, Flamm RK. 2017. Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015. Antimicrob Agents Chemother 61:e00465-17. https://doi.org/10.1128/AAC.00465-17.

          Article
          PMC5487642 PMC5487642 5487642 00465-17
          10.1128/AAC.00465-17
          5487642
          28483953
          7a2d4ed5-dbc0-436d-b843-2850d4985081
          Copyright © 2017 American Society for Microbiology.

          All Rights Reserved.

          History
          : 3 March 2017
          : 9 April 2017
          : 29 April 2017
          Page count
          Figures: 0, Tables: 3, Equations: 0, References: 15, Pages: 6, Words: 3456
          Funding
          Funded by: Merck (Merck & Co., Inc.) https://doi.org/10.13039/100004334
          Award Recipient : Dee Shortridge Award Recipient : Mariana Castanheira Award Recipient : Michael A. Pfaller Award Recipient : Robert K. Flamm
          Categories
          Susceptibility
          Custom metadata
          July 2017

          Pseudomonas aeruginosa ,ceftolozane-tazobactam,United States,susceptibility,MDR,XDR

          Comments

          Comment on this article